Research never stops

Oncology

Building long-term vision in novel fields of oncology

Molecule(s) Indication
(mechanism)
Partner Status Next milestone Commercials
TargetKDM

Various

(Epigenetic targets)

Belfer Institute Pre-clinical Pharma partnership ND
TargetImmuniT Cancer immunotherapy Apeiron/Sanofi Hit-to-Lead ND Research payments, milestones, royalties
TargetDBR Glioblastoma (brain tumour) Yale University Hit-to-Lead Pharma partnership ND
EVT601 Cancer Sanofi Pre-clinical Start of Phase I

ND

EVT701

Cancer

Sanofi

Pre-clinical

Start of Phase I

ND

EVT801

Cancer

Sanofi

Pre-clinical

Start of Phase I ND

Oncology

Belfer Institute/TargetKDM

- read more

Apeiron/Sanofi/TargetImmuniT

- read more

Yale/TargetDBR

- read more